Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Change of Adviser

22nd Oct 2021 07:00

RNS Number : 8807P

Ideagen PLC

22 October 2021

Ideagen PLC

Appointment of Corporate Broker

Ideagen PLC (AIM: IDEA), a leader in compliance software for regulated industries, today announces the appointment of Numis Securities Limited as its joint corporate broker with immediate effect.

Enquiries:

Ideagen plc	01629 699 100
Richard Longdon, Non-Executive Chairman
Ben Dorks, Chief Executive Officer
Emma Hayes, Chief Financial Officer


FTI Consulting	020 3727 1000
Jamie Ricketts	[email protected]
Dwight Burden Valerija Cymbal

About Ideagen plc

Ideagen's software helps companies comply with regulation and manage risk.

Ideagen is a leader in the £3 billion regulatory and compliance software market, serving highly regulated industries such as life sciences, healthcare, banking and finance and insurance. Ideagen has made twenty acquisitions to build its market leadership.

More than 5,700 organisations use Ideagen's software, including nine of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of leading pharmaceutical firms.

Ideagen has a diversified customer base including blue chip, global brands such as Heineken, British Airways, BAE, Aggreko, US Navy, Bank of New York and Johnson Matthey, as well as 250 hospitals across the UK and US.

Ideagen is headquartered in the UK, listed on the London Stock Exchange AIM market (Ticker: IDEA.L), and has key hubs in the UK, EU, US, Middle East and South East Asia. For further information please visit www.ideagen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPPPGQCUUPGGRG

Related Shares:

FTSE 100 Latest

Value8,275.66

Change0.00